← Human Trials & Peer-Reviewed Studies
Vitamin D supplementation in obese type 2 diabetes subjects in Ajman, UAE: a randomized controlled double-blinded clinical trial.
Plain-language guide to PMID 25406966 (2015): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 2 participants.
Key Facts
- PMID
- 25406966
- Journal
- European journal of clinical nutrition
- Year
- 2015
- Study type
- Randomized Controlled Trial
- Authors
- Sadiya A et al. (8 authors)
- DOI
- 10.1038/ejcn.2014.251
- Registered trial
- NCT02101151
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.
To study the effect of Vitamin D3 supplementation on metabolic control in an obese type 2 diabetes Emirati population.
Who Took Part
The abstract describes 2 participants taking part.
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
This randomized double-blind clinical trial was conducted with 87 vitamin D-deficient obese, type 2 diabetic participants.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
The vitamin D-group (n=45) and the placebo group (n=42) were matched for gender, age, HbA1c and 25-hydroxy vitamin D (25(OH) D) at the baseline.
What Was Measured
PubMed files the paper under topics including Body Mass Index, Calcifediol, Cholecalciferol, Diabetes Mellitus, Type 2, Dietary Supplements, Glycated Hemoglobin and Hyperparathyroidism, Secondary.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 2 participants.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2015 (European journal of clinical nutrition), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.